Selection and identification of a novel ssDNA aptamer targeting human skeletal muscle

Bioactive Materials

卷:20

Xiao Chen¹  Yijun Yuan²  Mingri Zhao³  Xiaoxiang Ren⁴  Jin Cui⁵  Yingying Jing⁵  Han Liu⁵  Jiacan Su⁵  Yan Hu⁵  Shuming Sun⁶  Yanpeng Wang⁶  Yafei Han⁷ 

[1] Corresponding author.;

[2] Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, 410013, China;

[3] Center for Medical Genetics &

[4] Department of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China;

[5] Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China;

[6] Molecular Biology Research Center, Center for Medical Genetics, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, 410078, China;

[7] Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, 410082, China;

关键词: Aptamer;    SELEX;    Human skeletal muscle;    Target delivery;    Nanoliposomes;   

DOI  :  

来源: DOAJ

【 摘 要 】

Skeletal muscle disorders have posed great threats to health. Selective delivery of drugs and oligonucleotides to skeletal muscle is challenging. Aptamers can improve targeting efficacy. In this study, for the first time, the human skeletal muscle-specific ssDNA aptamers (HSM01, etc.) were selected and identified with Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The HSM01 ssDNA aptamer preferentially interacted with human skeletal muscle cells in vitro. The in vivo study using tree shrews showed that the HSM01 ssDNA aptamer specifically targeted human skeletal muscle cells. Furthermore, the ability of HSM01 ssDNA aptamer to target skeletal muscle cells was not affected by the formation of a disulfide bond with nanoliposomes in vitro or in vivo, suggesting a potential new approach for targeted drug delivery to skeletal muscles via liposomes. Therefore, this newly identified ssDNA aptamer and nanoliposome modification could be used for the treatment of human skeletal muscle diseases.

【 授权许可】

Unknown